An interventional study of Measurement of peak nasal flow. in Acute Rhinitis, Nasal Obstruction and Rhinosinusitis, sponsored by Laboratoires Gilbert. Recruiting at 5 sites in France. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by Laboratoires Gilbert · Not applicable, Interventional, and Treatment
The purpose of this pre-market clinical investigation is to assess the safety and the performance of decongestant seawater spray pocket valve enriched with essential oils by Gilbert Laboratories. The study will evaluate the results of acute rhinitis associated with nasal obstruction using the decongestant seawaterspray pocket valve enriched with essential oils over a 8 day period.
219 studies on the registry are indexed under Common Cold; 23 are open to participants now.
This study's planned enrollment of 101 is below the median of 150 across 184 interventional studies indexed under Common Cold.
Browse Common Cold studies →Laboratoires Gilbert is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This arm is made up of major patients. Nasal flow point measurements will be performed at D0 and D3.
Device: Measurement of peak nasal flow.
This arm is made up of minor patients. Unlike arm A, nasal flow measurements will not be performed at D0 and D3.
Peak nasal flow measurements will be performed before and after the first use of the spray at D0, as well as after the use of the spray at the medical office at D3 (only for arm A).
Performance of the Gilbert Laboratories pocket valve spray.
Proportion of patient presenting a change of the symptom "nasal obstruction" by at least 1 pt, in the SNOT22 Test (item 22), between Day 0 (at inclusion in the office before use of the spray) and Day 3 (in the evening after last daily use of the spray). This item is scaled from 0 to 5, 5 being the worst value.
Time frame: From Day 0 to Day 3
Change of nasal obstruction between Day 0 and Day 3
Proportion of patients with a change in Peak Inspiratory Nasal Flow value of at least 30 L/min between Day 0 (before use of the spray) and Day 3 (after use of the spray) (arm A). \[0 - 350 L/min\] 350 L/min means a better outcome.
Time frame: From Day 0 to Day 3
Immediate change of nasale obstruction at D0 on first use (Arm A)
Proportion of patients with a change in Peak Inspiratory Nasal Flow value of at least 30 L/min from pre- to post-spray measurements at Day 0 (arm A). \[ 0 - 350 L/min\] 350 L/min means a better outcome.
Time frame: At Day 0
Subjective feeling of reduced nasal obstruction on each day of use (arms A+B).
Proportion of patients with a reduction in the symptom "nasal obstruction" of at least 1pt, on SNOT22 (Sino-Nasal Outcome Test 22), and on each day of use (from Day 0 to Day 6) (arms A+B). This item is scaled from 0 to 5, 5 being the worst value.
Time frame: From Day 0 to Day 6
Subjective feeling of nasal cavity cleansing (freshness) each day of use (arms A+B).
Proportion of patients who experienced nasal cavity cleansing (feeling of freshness), on Patient Questionnaire, and on each day of use (from Day 0 to Day 6) (arms A+B).
Time frame: From Day 0 to Day 6
Subjective feeling of nasal secretion thinning on each day of use (arms A+B).
Proportion of patients with a change in the symptom "thick nasal discharge" of at least 1pt, on SNOT22, and on each day of use (Day 0 to Day 6) (arms A+B). This item is scaled from 0 to 5, 5 being the worst value.
Time frame: From Day 0 to Day 6
Subjective feeling of relief of nasal irritation (mucous membrane) on each day of use (arms A+B).
Proportion of patients who experienced relief of nasal (mucosal) irritation, on each day of use (Day 0 to Day 6) (arms A+B).
Time frame: From Day 0 to Day 6
Subjective feeling of relief of nasal itching on each day of use (arms A+B).
Proportion of patients who experienced relief of nasal itching, on Patient Questionnaire, and on each day of use (Day 0 to Day 6) (arms A+B).
Time frame: From Day 0 to Day 6
Speed of action at which the patient feels (subjectively) a decrease in nasal obstruction at D0 and D3 (arms A+B).
Proportion of patients with a change in immediate nasal obstruction after use of the spray, on Patient Questionnaire, at Day 0 and Day 3 (arms A+B).
Time frame: At Day 0 and Day 3
Speed of action at which the patient feels (subjectively) a purification of his nasal cavities (sensation of freshness) at D0 and D3 (arms A+B).
Proportion of patients who experienced immediate nasal cleansing (feeling of freshness) after use of the spray at Day 0 and Day 3 (arms A+B).
Time frame: At Day 0 and Day 3
Improvement in the patient's quality of life after 7 days of use (arms A+B).
Proportion of patients who experienced an improvement in quality of life, defined as an increase of at least 1pt on a scale of 0-10 between Day 0 and Day 6 (A+B arm). 10 mean a better value.
Time frame: From Day 0 to Day 6
Patient satisfaction with the medical device after 7 days of use (arm A+B).
Proportion of patients satisfied with the medical device, on a 4-point scale, at Day 6 (arm A+B). The better value is "very satisfied" and the worst value is "very unsatisfied". Proportion of patients who would recommend the medical device at Day 6 (arms A+B). Proportion of patients who will continue to use the medical device , and the reason if not, (arms A+B).
Time frame: At Day 6
Facility of use of the medical device after 7 days of use (arm A+B)
Proportion of patients who find the medical device easy to use, on day 6 (Arms A+B)
Time frame: At Day 6
Evolution of the overall severity of symptoms (arm A+B).
Mean SNOT22 score on each day. Comparison of SNOT22 score at Day 3 versus Day 0 baseline (arms A+B). \[ 0 to 220 \] 0 is the better value.
Time frame: At Day 0 and Day 3
Sensations of tingling and transient irritation (arms A+B).
Proportion of patients with at least 1 adverse event between 1st and last use of the medical device among the following adverse events (arms A+B): * Tingling sensations * Sensations of transient irritation
Time frame: From Day 0 to Day 6
All adverse events reported by patients using the pocket valve spray after 7 days of use (arm A+B).
All adverse events reported by the patient during the study (arm A+B).
Time frame: From Day 0 to Day 7
Not enrolling at this site.
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Laboratoires Gilbert